Unlocking New Possibilities: Oral Therapeutics in Psoriasis & Melasma

Abstract

Psoriasis and melasma are dermatological conditions with significant clinical and psychosocial impact. While topical and procedural treatments remain foundational, oral therapeutics have emerged as vital options, especially for refractory cases or extensive disease. This review synthesizes contemporary evidence regarding oral therapies in psoriasis and melasma, elucidating mechanisms, efficacy, safety, and guideline recommendations, and discusses recent advances shaping clinical practice.

Introduction

Psoriasis, a chronic immune-mediated disorder, and melasma, an acquired hyperpigmentation, present unique management challenges due to their multifactorial etiologies and variable clinical courses. Both conditions can severely affect quality of life, prompting the need for effective systemic interventions when topical modalities prove insufficient. This article critically examines the evolving landscape of oral therapeutics, integrating mechanistic insights and recent clinical data to inform evidence-based management.

Epidemiology / Disease Burden

Psoriasis affects approximately 2-3% of the global population, with prevalence varying by ethnicity and geography. It is associated with significant comorbidities, including metabolic syndrome, cardiovascular disease, and depression, amplifying its societal impact. Melasma predominantly affects women of reproductive age, with higher incidence among individuals with Fitzpatrick skin types III-V. Both conditions are linked to substantial psychosocial distress, underscoring the importance of effective therapeutic strategies.

Pathophysiology

Psoriasis is characterized by dysregulated immune activation, particularly involving Th17 and Th1 pathways, leading to keratinocyte hyperproliferation and chronic inflammation. Genetic susceptibility and environmental triggers contribute to disease onset and exacerbation. Melasma, conversely, arises from complex interplay between genetic predisposition, hormonal influences (notably estrogen), UV exposure, and abnormal melanogenesis. Recent research highlights the role of cutaneous inflammation and vascular factors in melasma pathogenesis, suggesting new avenues for systemic intervention.

Risk Factors

Key risk factors for psoriasis include family history, obesity, smoking, stress, and infections. Melasma risk is heightened by female gender, pregnancy, use of oral contraceptives, certain medications, and chronic UV exposure. Understanding these risk profiles is critical for risk stratification and tailoring systemic therapy, especially in populations predisposed to adverse drug reactions.

Clinical Features

Psoriasis typically presents with well-demarcated erythematous plaques, covered by silvery scales, commonly on extensor surfaces, scalp, and sacral regions. Nail and joint involvement may occur, manifesting as pitting, onycholysis, or psoriatic arthritis. Melasma manifests as symmetrical hyperpigmented macules and patches, often on sun-exposed areas of the face. Both conditions may exhibit chronicity, with periods of remission and exacerbation.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by histopathology in atypical cases. Key histological features include acanthosis, parakeratosis, and Munro microabscesses. Melasma is diagnosed based on characteristic clinical presentation, with Wood’s lamp examination aiding in depth assessment. Dermoscopy and histopathology may assist in differentiating melasma from other pigmentary disorders.

Treatment & Management

Topical therapies, including corticosteroids, vitamin D analogues, and calcineurin inhibitors, are first-line for mild psoriasis. Systemic agents are reserved for moderate-to-severe disease, recalcitrant cases, or those affecting quality of life. Conventional oral agents include methotrexate, cyclosporine, and acitretin, each with distinct mechanisms and monitoring requirements. For melasma, first-line management involves rigorous photoprotection and topical depigmenting agents (hydroquinone, retinoids, azelaic acid). However, oral therapies are increasingly explored, especially in refractory cases or extensive disease.

Recent Advances / Emerging Therapies

In psoriasis, the advent of oral small molecules, notably apremilast (a phosphodiesterase-4 inhibitor), has broadened the therapeutic armamentarium, offering effective disease control with favorable safety profiles. Janus kinase (JAK) inhibitors, such as tofacitinib and deucravacitinib, have demonstrated efficacy in clinical trials, expanding options for patients unsuitable for biologics. For melasma, oral tranexamic acid has emerged as a promising adjunct, modulating melanogenesis and vascular components, although concerns about thromboembolic risk persist. Polypodium leucotomos extract and oral antioxidants are under investigation, with early evidence suggesting benefit in pigmentation reduction and photoprotection.

Guideline Recommendations

Current guidelines advocate for individualized therapy in psoriasis, balancing efficacy, safety, and comorbidity profiles. Methotrexate remains a mainstay for moderate-to-severe disease, while apremilast is recommended for patients with contraindications to immunosuppressants or biologics. Cyclosporine is reserved for short-term use due to nephrotoxicity risk. In melasma, oral tranexamic acid may be considered for recalcitrant cases, with careful patient selection and monitoring. Professional societies emphasize the need for shared decision-making, regular monitoring for adverse events, and integration of photoprotection in all management plans.

Conclusion

Oral therapeutics have revolutionized the management of psoriasis and melasma, offering new hope for patients with difficult-to-treat disease. Advances in understanding disease mechanisms have facilitated the development of targeted oral agents, yielding improved efficacy and safety. Ongoing research into emerging molecules and optimization of existing therapies is likely to further refine clinical practice. Careful patient selection, risk-benefit assessment, and adherence to guideline recommendations remain central to maximizing therapeutic outcomes in these chronic dermatological conditions.